Lung Cancer
Volume 62, Issue 1 , Pages 45-54 , October 2008

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin

  • Kota Iwahori

      Affiliations

    • Department of Respiratory Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
    • Laboratory for Immune Signal, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan
    • ,
  • Tadashi Osaki

      Affiliations

    • Department of Respiratory Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 6 6879 3833; fax: +81 6 6879 3839.
    • ,
  • Satoshi Serada

      Affiliations

    • Laboratory for Immune Signal, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan
    • ,
  • Minoru Fujimoto

      Affiliations

    • Laboratory for Immune Signal, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan
    • ,
  • Hidekazu Suzuki

      Affiliations

    • Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1 Habikino, Habikino, Osaka 583-8588, Japan
    • ,
  • Yoshiro Kishi

      Affiliations

    • Department of Research and Development, Ina Institute, Medical & Biological Laboratories, Co., Ltd., 1063-103 Terasawaoka, Ina, Nagano 396-0002, Japan
    • ,
  • Akihito Yokoyama

      Affiliations

    • Department of Hematology and Respiratory Medicine, Kochi University, 185-1, Okohchou-kohatu, Nanngoku, Kohchi 783-8505, Japan
    • ,
  • Hironobu Hamada

      Affiliations

    • Department of Integrated Medicine and Informatics, Ehime University Graduate School of Medicine, Sizukawa, Ohonn, Ehime 791-0295, Japan
    • ,
  • Yoshihiro Fujii

      Affiliations

    • Department of Research and Development, Ina Institute, Medical & Biological Laboratories, Co., Ltd., 1063-103 Terasawaoka, Ina, Nagano 396-0002, Japan
    • ,
  • Kentaro Yamaguchi

      Affiliations

    • Department of Product Development, Ina Institute, Medical & Biological Laboratories, Co., Ltd., 1063-103 Terasawaoka, Ina, Nagano 396-0002, Japan
    • ,
  • Tomonori Hirashima

      Affiliations

    • Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1 Habikino, Habikino, Osaka 583-8588, Japan
    • ,
  • Kaoru Matsui

      Affiliations

    • Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1 Habikino, Habikino, Osaka 583-8588, Japan
    • ,
  • Isao Tachibana

      Affiliations

    • Department of Respiratory Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
    • ,
  • Yusuke Nakamura

      Affiliations

    • Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
    • ,
  • Ichiro Kawase

      Affiliations

    • Department of Respiratory Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
    • ,
  • Tetsuji Naka

      Affiliations

    • Laboratory for Immune Signal, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan

Received 30 October 2007 ,Revised 30 January 2008 ,Accepted 14 February 2008.

References 

  1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  2. Stahel RA. Malignant pleural mesothelioma: a new standard of care. Lung Cancer. 2006;54(Suppl 2):S9–S14
  3. Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E. The Mesothelioma epidemic in Western Europe: an update. Br J Cancer. 2004;90:1022–1024
  4. Leithner K, Leithner A, Clar H, Weinhaeusel A, Radl R, Krippl P, et al. Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40. Orphanet J Rare Dis. 2006;1:44
  5. Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 2006;49:1–7
  6. Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945–2002. Int J Occup Environ Health. 2003;9:206–217
  7. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996;93:136–140
  8. Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer. 2004;4:19
  9. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006;15:1014–1020
  10. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA. 1999;96:11531–11536
  11. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612–1616
  12. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, et al. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 2006;97:928–932
  13. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res. 2006;12:4225–4231
  14. Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res. 2005;11:5840–5846
  15. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937–3942
  16. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem. 2007;53:666–672
  17. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006;173:1155–1160
  18. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12:447–453
  19. Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int. 2006;56:649–654
  20. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest. 2007;132:1239–1246
  21. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;5076–5081
  22. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13:2928–2935
  23. Khan WN, Hammarstrom S. Biosynthesis of carcinoembryonic antigen (CEA) gene family members expressed in human tumor cell lines: evidence for cleavage of the glycosyl phosphatidyl inositol (GPI) anchor by GPI-PLC and GPI-PLD. Biochem Int. 1991;25:723–731
  24. Ernst A, Hellmich S, Bergmann A. Proneurotensin 1–117, a stable neurotensin precursor fragment identified in human circulation. Peptides. 2006;27:1787–1793
  25. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 1992;52:181–186
  26. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994;269:805–808
  27. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992;50:373–381
  28. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418–1428

PII: S0169-5002(08)00073-1

doi: 10.1016/j.lungcan.2008.02.012

Lung Cancer
Volume 62, Issue 1 , Pages 45-54 , October 2008

Article Tools

* Image Usage & Resolution